EUVIMEDEUVIMED entdecken
Crossref

Predictive factors for responders to deucravacitinib treatment in patients with psoriasis

Teppei Hagino iD, Marina Onda, Hidehisa Saeki iD, Eita Fujimoto, Naoko Kanda iD

The Journal of Dermatology · 2025-03 · 52 (3) · 551-555

DOI: 10.1111/1346-8138.17601 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, online erschienen am 26.12.2024. Verfasst von Teppei Hagino und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Hauptthemen laut MEDLINE: Psoriasis, Protein Kinase Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The tyrosine kinase 2 inhibitor deucravacitinib is therapeutically effective for psoriasis. However, predictive factors for high responses to deucravacitinib have not been examined in a real‐world clinical study. Our study aimed to identify predictive factors for responders to deucravacitinib. Therefore, a retrospective study was conducted on 74 patients with psoriasis treated with deucravacitinib (6 mg/day) at week 16 of treatment from January 2023 to February 2024. Patients were classified into responders (achievers of a static Physician's Global Assessment [sPGA] of 0 or 1 with ≥2‐point improvement from basal sPGA) and non‐responders (non‐achievers). We compared baseline values of clinical and laboratory indexes between responders and non‐responders. Multivariate logistic regression analysis was used to identify variables predicting responders. Forty‐one patients (55.4%) were considered as responders at week 16. Multivariate logistic regression analysis revealed that the response to deucravacitinib was associated with higher age (odds ratio [OR] 1.04; 95% confidence interval [CI] 1.01–1.08; p = 0.0222) and lower body mass index (BMI) (OR 0.825; 95% CI 0.713–0.955; p = 0.0101). Higher age and lower BMI may predict a higher response to deucravacitinib (6 mg/day) at week 16 of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisProtein Kinase InhibitorsHumansMaleFemaleRetrospective StudiesMiddle AgedAdultTreatment OutcomeAgedAge FactorsBody Mass IndexSeverity of Illness Index

Stichwörter der Autor:innen

agebody mass indexdeucravacitinibpsoriasisresponder

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
  • Department of Dermatology, Nippon Medical School, Tokyo, Japan.
  • Fujimoto Dermatology Clinic, Funabashi, Japan.

ORCID-Profile: Teppei Hagino, Hidehisa Saeki, Naoko Kanda

Zitieren

APA

Hagino, T., Onda, M., Saeki, H., Fujimoto, E., & Kanda, N. (2025). Predictive factors for responders to deucravacitinib treatment in patients with psoriasis. The Journal of Dermatology, 52(3), 551-555. https://doi.org/10.1111/1346-8138.17601

Vancouver

Hagino T, Onda M, Saeki H, Fujimoto E, Kanda N. Predictive factors for responders to deucravacitinib treatment in patients with psoriasis. The Journal of Dermatology. 2025;52(3):551-555. doi:10.1111/1346-8138.17601

BibTeX
@article{Hagino2025,
  author = {Hagino, Teppei and Onda, Marina and Saeki, Hidehisa and Fujimoto, Eita and Kanda, Naoko},
  title = {Predictive factors for responders to deucravacitinib treatment in patients with psoriasis},
  journal = {The Journal of Dermatology},
  year = {2025},
  volume = {52},
  number = {3},
  pages = {551--555},
  doi = {10.1111/1346-8138.17601}
}
Kostenlos starten →